# Norepinephrine Infusion Versus Midodrine & Octreotide in Patients With Hepatorenal Syndrome Type 1.

> **NCT03455322** · PHASE4 · COMPLETED · sponsor: **National Hepatology & Tropical Medicine Research Institute** · enrollment: 60 (actual)

## Conditions studied

- Renal Impairment in Hepatorenal Syndrome

## Interventions

- **DRUG:** norepinephrine versus midodrine & octreotide

## Key facts

- **NCT ID:** NCT03455322
- **Lead sponsor:** National Hepatology & Tropical Medicine Research Institute
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-15
- **Primary completion:** 2020-04-20
- **Final completion:** 2020-07-10
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2021-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03455322

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03455322, "Norepinephrine Infusion Versus Midodrine & Octreotide in Patients With Hepatorenal Syndrome Type 1.". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03455322. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*